Cosmoss, which debuted in September 2022, is described as “self-care created for life’s modern journeys”. The brand draws on the extraordinary life experience of Kate Moss, who is ready to share her journey of self-acceptance and freely be herself. The brand offers a range of products, such as Golden Nectar CBD and Pro-Collagen Oil, Face Cream, Face Cleanser, Sacred Mist fragrance, and Dawn and Dusk Teas. CBD and bakuchiol (a plant alternative to retinol) are the star ingredients within the skincare products, offering support for stressed complexions. The fragrance mist sees an aromatic blend of bergamot, tuberose and grounding woods to uplift the spirits. The tea, rare in a celebrity-fronted line-up, makes perfect sense here as it completes the whole self-care ritual that the brand prides itself on.
Moss, who has openly spoken about her love of daily yoga and meditation, said that she started spending a lot of time in her garden during the pandemic and noticing flowers that she didn’t even know she had. She said that her garden has become her favourite place now, where she feels happiest. She also said that each product has been meticulously crafted with wellbeing in mind, and that each ritual opens a door to balance, restoration, and love.
The US Drug Laws: A Barrier for Cosmoss
However, Moss’s wellness brand has encountered a legal obstacle in the US, as the US Patent and Trademark Office has denied her application to register Cosmoss in America. The reason is that the application identifies a connection to cannabidiol (CBD), which is a nonpsychoactive constituent of the cannabis plant. The office stated that goods containing CBD derived from cannabis that meet the definition of “marijuana” are illegal under the federal Controlled Substances Act, and that no other cannabis-derived drug products have been approved. The office also stated that the application violates the Federal Food, Drug and Cosmetic Act, which prohibits the introduction of CBD products into interstate commerce.
The office gave Moss six months to respond to the rejection, or else the application will be abandoned. The office also asked Moss to provide a written statement that clearly and accurately indicates the nature of the goods and services, and that confirms that they comply with both the Controlled Substances Act and the Federal Food, Drug and Cosmetic Act.
The Future of Cosmoss: A Hope for Change
Moss has not commented on the rejection of her application, but she may still have a chance to bring Cosmoss to the US market, if she can prove that her products are legal and safe. The US drug laws are constantly evolving, and some states have legalized or decriminalized the use of cannabis for medical or recreational purposes. The US Food and Drug Administration (FDA) has also approved one cannabis-derived drug product, Epidiolex, which contains CBD and is used to treat seizures associated with two rare forms of epilepsy. The FDA has also stated that it is working to provide a regulatory framework for the lawful marketing of CBD products, and that it is open to scientific data and information about the potential benefits and risks of CBD.
Cosmoss may also benefit from the growing popularity and demand for CBD products in the US, as more consumers are seeking natural and alternative remedies for various health and wellness issues. According to a report by Grand View Research, the US CBD market size was valued at $4.6 billion in 2021, and is expected to grow at a compound annual growth rate of 40.4% from 2022 to 2028. The report also stated that the skincare segment is expected to witness the fastest growth, as CBD is known to have anti-inflammatory, antioxidant, and anti-aging properties.
Kate Moss’s Cosmoss brand faces legal hurdles in the US over CBD products, as the US Patent and Trademark Office rejects her application to register Cosmoss in America.
David Johnson is a respected writer known for his expertise in crafting compelling articles about cannabis. With a passion for exploring the intersection of cannabis, health, and wellness, he sheds light on the therapeutic properties and potential uses of this versatile plant. David’s in-depth analysis and thought-provoking commentary offer readers a deeper understanding of the evolving landscape of cannabis legislation, consumption methods, and industry trends.
